Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But ...
Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But ...
For millions of people with HIV (PWH), a daily regimen of medications is a lifelong necessity. If they stop taking antiretroviral therapy (ART), the virus usually rushes back within weeks. But this ...
Antiretroviral drugs for HIV infection have enabled most people living with the virus to live long and healthy lives. However, a small portion of people experience detectable—and worrisome—traces of ...
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...
CAR-T cell therapy is already a potent treatment for certain cancers. Now, a small study is showing early promise for managing HIV. A Miracle cancer therapy that involves engineering a patient’s own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results